fot. Jacek Taran

Head of the Chair of Bioethics and Health Psychology

m.waligora@uj.edu.pl

Professor and Vice Dean at the Faculty of Health Science, Jagiellonian University. Former Harvard Fulbrighter (Center for Bioethics 2017/18). He directs Research Ethics in Medicine Study Group (REMEDY).

Selected publications:

• Klas K, Strzebonska K, Buedo P, Włodarczyk A, Gordon S, et al. (2024) Seamless trials in oncology: A cross-sectional analysis of characteristics and reporting. PLOS ONE 19(12): e0312797. https://doi.org/10.1371/journal.pone.0312797
• Klas, K., Strzebonska, K., Zaborowska, Ł., Krawczyk, T., Włodarczyk, A., Bąk-Kuchejda, U., Polak, M., Van Wambeke, S., Waligora M. Risk and Benefit for Basket Trials in Oncology: A Systematic Review and Meta-Analysis. Targeted Oncology 2024 Oct 2. DOI: 10.1007/s11523-024-01107-3
• Krawczyk, T., Piasecki, J., Wasylewski, M., Waligora, M. (2024). Ethics of research engagement with Deaf people. A qualitative evidence synthesis. The Journal of Deaf Studies and Deaf Education, Volume 29, Issue 4, October 2024, Pages 443–455, https://doi.org/10.1093/jdsade/enae024
• Buedo P, Prieto E, Perek-Białas J, Odziemczyk-Stawarz I, Waligora M. More ethics in the laboratory, please! Scientists’ perspectives on ethics in the preclinical phase. Account Res. 2024 Jan 18:1-16, DOI: 10.1080/08989621.2023.2294996
• Buedo P, Bianchini A, Klas K, Waligora M. Bioethics of somatic gene therapy: what do we know so far? Curr Med Res Opin. 2023 Sep 29:1-17. DOI: 10.1080/03007995.2023.2257600
• Bicer S, Hutchinson N, Feldhake E, Nelson A, Oliviero E, Waligóra M, Kimmelman J. Timing for First-in-Minor Clinical Trials of New Cancer Drugs. J Pediatr. 2023 Aug 30:113705
• Klas K, Strzebonska K, Waligora M. Ethical challenges of clinical trials with a repurposed drug in outbreaks Med Health Care and Philos (2023). doi.org/10.1007/s11019-023-10140-4
• Buedo P, Odziemczyk I, Perek-Białas J, Waligora M. How to embed ethics into laboratory research. Account Res. 2023 Jan 17:1-20, DOI: 10.1080/08989621.2023.2165916
• Hutchinson N, Klas K, Carlisle BG, Polak M, Kimmelman J, Waligora M. Competition for recruitment in SARS-CoV-2 Trials in the United States: a longitudinal cohort analysis. BMC Res Notes 15, 368 (2022). doi.org/10.1186/s13104-022-06263-1
• Hutchinson N, Klas K, Carlisle BG, Kimmelman J, Waligora M. How informative were early SARS-CoV-2 treatment and prevention trials? a longitudinal cohort analysis of trials registered on ClinicalTrials.gov. PLoS One. 2022;17(1):e0262114.
• Waligora M., & Klas K. (2022). Masking. In B. Frey (Ed.), The SAGE encyclopedia of research design (Vol. 1, pp. 860-861). SAGE Publications, Inc.
• Strzebonska K, Blukacz M, Wasylewski MT, Polak M, Gyawali B, Waligora M. Risk and benefit for umbrella trials in oncology: a systematic review and meta-analysis. BMC Med. 2022; 20:219. doi: 10.1186/s12916-022-02420-2
• Strzebonska K, Wasylewski MT, Zaborowska L, Polak M, Slugocka E, Stras J, Blukacz M, Gyawali B, Waligora M. Risk and Benefit for Targeted Therapy Agents in Pediatric Phase II Trials in Oncology: A Systematic Review with a Meta-Analysis. Target Oncol. 2021; 16(4):415-424. doi:10.1007/s11523-021-00822-5
• Wasylewski MT, Strzebonska K, Koperny M, Polak M, Kimmelman J, Waligora M (2020), Clinical development success rates and social value of pediatric Phase 1 trials in oncology, PLoS ONE 15(6): e0234911. doi: 10.1371/journal.pone.0234911
• Strzebonska K, Wasylewski MT, Zaborowska L, Riedel N, Wieschowski S, Strech D, Waligora M. Results dissemination of registered clinical trials across Polish academic institutions: a cross-sectional analysis, BMJ Open. 2020 Jan 22;10(1):e034666. doi: 10.1136/bmjopen-2019-034666
• Strzebonska K, Waligora M, Umbrella and basket trials in oncology: ethical challenges, BMC Med Ethics. 2019 Aug 23;20(1):58. doi: 10.1186/s12910-019-0395-5
• Strzebonska K, Waligora M, Underestimation of Harms in Phase I Trials, The Journal of Law, Medicine & Ethics, 2019 Jun;47(2):334-335. doi: 10.1177/1073110519857290
• Kimmelman J, Waligora M, Fernandez Lynch H, Participants Protection in Phase1 Pediatric Cancer Trials, JAMA Pediatrics 2019;173(1):8-9. doi:10.1001/jamapediatrics.2018.3629
• Waligora M, Bala MM, Koperny M, Wasylewski MT, Strzebonska K, Jaeschke RR, Wozniak A, Piasecki J, Sliwka A, Mitus JW, Polak M, Nowis D, Fergusson D, Kimmelman J, Risk and surrogate benefit for pediatric Phase I trials in oncology: A systematic review with meta-analysis, PLoS Med 15(2): e1002505. doi: 10.1371/journal.pmed.1002505
• Waligora M, Strzebonska K, Wasylewski MT, Neither the Harm Principle nor the Best Interest Standard Should Be Applied to Pediatric Research, American Journal of Bioethics, 2018 Aug;18(8):72-74. doi: 10.1080/15265161.2018.1485762
• Piasecki J, Dranseika V, Waligora M, Should Epidemiological Studies Be Subject to Ethics Review?, Public Health Ethics, 2017, phx016. doi: 10.1093/phe/phx016
• Dranseika V, Gefenas E, Waligora M, Broadening the “Infrastructure Effect”: Lessons from the Early Development of Research Ethics in Eastern Europe, The American Journal of Bioethics, 2016 Jun; 16(6):26-8. doi: 10.1080/15265161.2016.1170243
• Mezinska S, Kakuk P, Mijaljica G, Waligóra M, O’Mathúna DP, Research in disaster settings: a systematic qualitative review of ethical guidelines, BMC Medical Ethics, 2016, 17:62. doi: 10.1186/s12910-016-0148-7
• Waligora M, Rozynska J, Piasecki J, Child’s objection to non-beneficial research: capacity and distress based models, Medicine, Health Care and Philosophy 2016 Mar;19(1):65-70. doi: 10.1007/s11019-015-9643-8
• M. Waligora, V. Dranseika, J. Piasecki, Child’s assent in research: Age threshold or personalisation?, BMC Medical Ethics 2014, 15:44. doi: 10.1186/1472-6939-15-44
• M. Waligora Failures in Clinical Trials in the European Union: Lessons from the Polish Experience, Science and Engineering Ethics 2013 Sep; 19(3):1087-98. doi:10.1007/s11948-012-9400-9

More information at the remedy.edu.pl